 BALA CYNWYD, Pa., May 21, 2021 GLOBE NEWSWIRE -- Larimar Therapeutics, Inc. Larimar Nasdaq: LRMR, a clinical-stage biotechnology company focused on developing treatments for Friedreichs ataxia FA and other complex rare diseases, today announced that it has executed a securities purchase agreement to raise gross proceeds of approximately 95 million in a private placement financing of common stock or pre-funded warrants to purchase common stock in lieu thereof. The financing included funds managed by Deerfield Management Company, L.P., Surveyor Capital a Citadel company Adage Capital Management, L.P., RA Capital Management, Cowen Healthcare Investments, Verition Fund Management and Vivo Capital, among others. Several members of Larimar senior management and Board of Directors also participated. 